Strategic Acquisition Pillar5 Pharma recently became part of ANJAC Health & Beauty through a 2022 acquisition, signaling potential cross-sell opportunities with ANJAC’s portfolio and distribution channels to expand reach in related healthcare and consumer health markets.

Ophthalmic Specialty As a leading CDMO with niche expertise in sterile ophthalmic solutions and multi dose preservative free formulations, Pillar5 offers a compelling partner for pharma companies seeking contract manufacturing capacity for sensitive eye care products.

Global Compliance With Health Canada and FDA inspections completed (2013) and no 483s on record, Pillar5 demonstrates a strong compliance track record, which can reduce regulatory risk for potential clients seeking reliable U.S. and Canadian manufacturing partners.

Solid Dose Footprint In addition to ophthalmics, Pillar5 provides solid dose manufacturing (tablets and capsules), enabling opportunities to diversify a client’s product mix and scale small- to mid-sized batch production for niche or specialty therapies.

Growth Readiness Revenue range of 25 to 50 million and an award-winning, scalable facility backed by a long-standing development and manufacturing team indicate capacity and experience to handle new programs, faster time-to-market timelines, and potential expansion collaborations.